ERBB2 and breast carcinoma: These findings are in line with prior studies, which reported that up to 34% of patients with breast cancer present with heterogeneous HER2 expression.25-28 Such phenotypic alterations significantly complicate the management of HER2-positive breast cancer, highlighting the inadequacy of systemic treatments predicated solely on the subtype of the primary tumor for achieving optimal efficacy.